Norditropin® FlexPro® pen

DRUG2 trials

Sponsors

Novo Nordisk A/S

Conditions

Growth DisorderGrowth Hormone Deficiency in ChildrenGrowth Hormone DisorderHealthy

Phase 1

A Trial to Investigate the Bioequivalence of Norditropin® (Somatropin) Versus Genotropin® (Somatropin) in Healthy Adult Subjects

CompletedNCT01943084

Novo Nordisk A/SGrowth Disorder, Healthy

Start: 2013-09-30End: 2013-10-31Updated: 2015-03-19

Phase 2

Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency

CompletedNCT02616562

Novo Nordisk A/SGrowth Hormone Deficiency in Children, Growth Hormone Disorder

Start: 2016-03-31End: 2024-09-26Updated: 2026-01-16

Related Papers

Seven-year Safety and Efficacy of Somapacitan in Children With GH Deficiency: Final Results From REAL 3.

2025-11-21

THU174 Model-Based Analysis Of IGF-I Response, Dosing, And Monitoring For Once-Weekly Somapacitan In Children With GH Deficiency

Journal of the Endocrine Society2023-10-01

Model-Based Analysis of IGF-I Response, Dosing, and Monitoring for Once-Weekly Somapacitan in Children With GH Deficiency

Journal of the Endocrine Society2023-09-0812 citations

Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH

The Journal of Clinical Endocrinology & Metabolism2023-07-0520 citations

Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety, and Treatment/Disease Burden Results From REAL 3

The Journal of Clinical Endocrinology & Metabolism2023-03-3027 citations

RF26 | PMON334 Once-Weekly Somapacitan in Growth Hormone Deficiency: 4-Year Efficacy and Safety Results from REAL 3, a Randomised Controlled Phase 2 Trial

Journal of the Endocrine Society2022-11-01

Effective GH Replacement With Once-weekly Somapacitan vs Daily GH in Children with GHD: 3-year Results From REAL 3

The Journal of Clinical Endocrinology & Metabolism2021-12-2940 citations

Once-Weekly Somapacitan Versus Daily Growth Hormone in Growth Hormone Deficiency: 2-Year Efficacy Results From REAL 3, a Randomized Phase 2 Trial

Journal of the Endocrine Society2021-05-011 citations

SAT-091 First Report of Disease-Specific Patient-Reported Outcomes from a Randomized Phase 2 Trial of Once-Weekly Somapacitan vs Daily GH in Children with GHD

Journal of the Endocrine Society2020-04-014 citations

SAT-LB12 Once-Weekly Somapacitan vs Daily Growth Hormone in Growth Hormone Deficiency: 2-Year Safety Results From Real 3, a Randomized Phase 2 Trial

Journal of the Endocrine Society2020-04-011 citations

Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial

The Journal of Clinical Endocrinology & Metabolism2020-01-0955 citations

SUN-247 Once-Weekly Somapacitan in Childhood Growth Hormone Deficiency: Efficacy and Safety Results of a Randomized, Open-Label, Controlled Phase 2 Trial (REAL 3)

Journal of the Endocrine Society2019-04-012 citations